• Amgen’s third-quarter 2026 GAAP EPS rose 19% year-over-year to $7.08, while total revenues increased 8% to $10.37 billion.
• Operating expenses fell 5% to $6.66 billion, while research and development spending climbed 11% to $2.11 billion year-over-year.
• MariTide’s Phase 3 cardiovascular outcomes trial completed enrollment of adults with established atherosclerotic cardiovascular disease and obesity or overweight.
• Full-year 2026 guidance projects GAAP EPS of $18.34–$19.28 and total revenues of $38.9 billion–$39.7 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87543) on November 03, 2026, and is solely responsible for the information contained therein.